Tyrosinase-derived melanoma epitopes (TYR epitopes)

Tyrosinase-derived melanoma epitopes are peptide fragments originating from the tyrosinase enzyme (UniProt: P14679), which is the rate-limiting enzyme in melanin biosynthesis (National Center for Biotechnology Information, 2024). These epitopes are processed intracellularly and presented on the cell surface by Major Histocompatibility Complex (MHC) class I molecules, most notably HLA-A*02:01 (Brichard et al., 1993). Because tyrosinase is highly expressed in melanocytes and overexpressed in the majority of melanomas, these peptides serve as critical tumor-associated antigens (TAAs) for cancer immunotherapy (Wolfel et al., 1994). Therapeutic strategies targeting these epitopes include peptide-based vaccines, dendritic cell vaccines, and T-cell receptor (TCR) engineered T-cell therapies designed to stimulate a CD8+ cytotoxic T-lymphocyte response (PubMed: 8144860). While these therapies aim to eliminate melanoma cells, they often result in "off-tumor, on-target" effects such as vitiligo, caused by the autoimmune destruction of healthy melanocytes (Vennegaard et al., 2020). Additionally, tumor cells may develop resistance through the downregulation of MHC molecules or the loss of tyrosinase expression (National Cancer Institute, 2024). Despite these challenges, tyrosinase-derived epitopes remain a primary focus for developing personalized vaccines and adoptive cell transfer protocols in metastatic melanoma (ClinicalTrials.gov, 2024).

Other names

Tyrosinase peptidesTYR-derived peptidesMelanoma-associated antigen tyrosinaseTyrosinase-related epitopesHLA-restricted tyrosinase antigens

Induction of antigen-specific cytotoxic T lymphocyte (CTL) responses through MHC-restricted presentation, leading to the targeted lysis of melanoma cells expressing the tyrosinase protein (Brichard et al., 1993; Wolfel et al., 1994).